Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability: 2022-2024

  • Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability fell 0.49% to $9.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $9.8 million, marking a year-over-year decrease of 0.49%. This contributed to the annual value of $9.8 million for FY2024, which is 0.49% down from last year.
  • Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability amounted to $9.8 million in Q4 2024, which was down 0.49% from $9.8 million recorded in Q4 2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability registered a high of $9.8 million during Q4 2023, and its lowest value of $453,000 during Q4 2022.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Non-Current Deferred Tax Liability value was $9.8 million (recorded in 2024), while the average stood at $6.7 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability soared by 2,063.13% in 2023, and later fell by 0.49% in 2024.
  • Over the past 3 years, Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability (Quarterly) stood at $453,000 in 2022, then spiked by 2,063.13% to $9.8 million in 2023, then dropped by 0.49% to $9.8 million in 2024.
  • Its last three reported values are $9.8 million in Q4 2024, $9.8 million for Q4 2023, and $453,000 during Q4 2022.